Navigation Links
In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer
Date:2/20/2008

Following its Approval, Erbitux Will Earn Gold-Standard Status in 2011,

According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on overall survival is the attribute that most influences oncologists' prescribing decisions in the treatment of stage III colon cancer. Clinical data and expert opinion shows that Bristol-Myers Squibb/ImClone Systems/Merck KGaA's Erbitux and Roche/Genentech/Chugai's Avastin have advantages in this attribute when used in combination with sales-leading FOLFOX4 treatment. FOLFOX4 is comprised of oxaliplatin (Sanofi-Aventis's Eloxatin/Eloxatine, Yakult's Elplat), 5- fluorouracil and leucovorin.

The new report entitled Colon Cancer (Stage III): Therapies Must Increase Survival over FOLFOX to Reach Blockbuster Status finds that surveyed oncologists indicate that a therapy which improves disease-free survival over FOLFOX4 at three years would earn a 60% patient share and achieve blockbuster status. The report forecasts that Avastin, in combination with FOLFOX4, will earn a 22% patient share in the U.S. stage III colon cancer market in 2016. Additionally, owing to its efficacy, safety and tolerability, Erbitux in combination with FOLFOX4 will earn gold-standard status for stage III colon cancer in 2011, following its approval for the indication in 2010 in the U.S. and Europe.

"When using both drugs in combination with FOLFOX4, experts gave Erbitux a slightly higher score over Avastin in safety and tolerability," said Marcus Hoyle, analyst at Decision Resources. "Oncologists indicated that the cardiovascular toxicity associated with VEGF inhibitors, such as Avastin, has a more negative impact on their prescribing decisions than the tissue disorders associated with EGFR inhibitors, such as Erbitux."

About the Report '/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Combination of Thyroid Medicines Not Necessary
2. Combination therapy improves survival for certain prostate cancer patients
3. Enlarged Prostate Treatment Study Shows Combination of AVODART(R) and Tamsulosin Provides Greater Benefit Than Either Medication Alone
4. Drug combination shrinks breast cancer metastases in brain
5. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
6. 3-drug combination extremely promising as first-line therapy for multiple myeloma
7. Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
8. ZOLINZA (vorinostat) in combination with bortezomib demonstrated clinical activity
9. Drug combination effective against multiple myeloma, researchers show
10. HIV drug resistance risk in mothers reduced by combination of common drugs
11. Quality Control: Nissan Quest to Feature micronAir(R) Combination Cabin Air Filters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Ohio (PRWEB) , ... June 30, 2015 , ... ... services nationwide, is pleased to announce it’s own Debby Mann, CPC, RCC, ROCC, ... Association (RBMA) Radiology Summit with the Special Recognition Award for her contribution to ...
(Date:6/30/2015)... ... June 30, 2015 , ... Trenton Health Team has been certified ... Accountable Care Organizations (ACO) in the State, serving the greater Trenton community. The ... Health Team ACO draws on the collaborative structure of THT, bringing together the vast ...
(Date:6/30/2015)... Lacey, WA (PRWEB) , ... June 30, 2015 ... ... AmerisourceBergen and Good Neighbor Pharmacy’s premier event and tradeshow, taking place July 29 ... technicians, and purchasing decision makers. , ThoughtSpot is a four-day event ...
(Date:6/30/2015)... California (PRWEB) , ... June 30, 2015 , ... The ... Power today at a media event in San Diego. Speakers and clean air advocates ... School of medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder and president ...
(Date:6/30/2015)... ... June 30, 2015 , ... University Post-Acute Rehab recently ... on the rehab center’s patients and their experiences at the facility. Medicare granted ... services available. Each patient attests to the high rating, which is predominantly based ...
Breaking Medicine News(10 mins):Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 3Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2
... Henry M. Jackson Foundation for the Advancement of Military ... of the Health Sciences doctoral students to receive fellowships ... 1988, is comprised of two Henry M. Jackson Fellowships ... a stipend and travel support. Kathleen Jones, a ...
... and the Food and Drug Administration (FDA) are ... vision-related patient-reported outcomes might be used to improve ... are being incorporated more frequently into randomized clinical ... that such patient-reported outcomes are key to providing ...
... TRAVERSE CITY, Mich., Aug. 25 Versus Technology, Inc. ... fiscal quarter ended July 31, 2009, a 1.8% decrease compared to ... Revenues for the nine months ended July 31, 2009, were ... 2008, a 3.0% decrease. Versus, quarterly revenues can vary significantly ...
... , , , , ... Judd is speaking up for those struggling with chronic pain -- a ... combined. Judd is lending her voice to the national education program ... instpain.com ) to raise awareness about the urgent need to ...
... ... Product, the New Personal Germ Protection Spray , ... Mount Kisco, NY (PRWEB) August 25, 2009 -- ... agency specializing in national brand OTC health and beauty products, recently signed an agreement ...
... , , CARROLLTON, Ga., Aug. ... Prime Enterprise(TM) benefits Health Systems, Independent Physician ... Centers (ASCs) and other organizations seeking centralized management of practice, ... User rights management enables enterprise users to set security and ...
Cached Medicine News:Health News:Henry M. Jackson Foundation names fellowship award winners 2Health News:Versus Technology Announces Third Quarter Results 2Health News:Versus Technology Announces Third Quarter Results 3Health News:Versus Technology Announces Third Quarter Results 4Health News:Versus Technology Announces Third Quarter Results 5Health News:Versus Technology Announces Third Quarter Results 6Health News:Versus Technology Announces Third Quarter Results 7Health News:Country Legend Naomi Judd Joins 'Partners Against Pain' 2Health News:Country Legend Naomi Judd Joins 'Partners Against Pain' 3Health News:Robin Leedy & Associates Wins Social Media Program For Union Springs Pharmaceuticals 2Health News:Greenway Medical Technologies' PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 2Health News:Greenway Medical Technologies' PrimeEnterprise Creates an Interconnected and Interoperable System of Community Health Information for Its Customers 3
(Date:6/30/2015)... , June 30, 2015  IGI Laboratories, Inc. ... based specialty generic pharmaceutical company, today announced it ... to the U.S. Food and Drug Administration (FDA) of ... submissions now pending at the FDA to twenty-seven. ... the Company, commented, "We believe our current pipeline of ...
(Date:6/30/2015)... Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX ... the development and commercialization of Locilex® (pexiganan cream ... announced underwritten public offering of 1,480,000 shares of ... option in full to purchase an additional 222,000 ... proceeds to Dipexium are expected to be approximately ...
(Date:6/30/2015)... 2015  Today, the National Mobility Equipment Dealers Association ... Mobility Awareness Month Local Heroes Contest on National TV. ... that received 1.3 million votes. The sponsors for the ... Mobility , and Valley Honda Dealers , with ... Vantage Mobility International (VMI) and ElDorado Mobility ...
Breaking Medicine Technology:IGI Laboratories, Inc. Announces Fifth ANDA Submission Of 2015 2Dipexium Announces Closing of Public Offering of Common Stock 2Dipexium Announces Closing of Public Offering of Common Stock 3NMEDA Announces National Contest Winners 2NMEDA Announces National Contest Winners 3
... Aug. 2 Novalar Pharmaceuticals, Inc., a specialty pharmaceutical company focused ... again been selected by leading dental industry magazine Dentistry Today as one ... 24th annual competition were published in the July issue.   , ... OraVerse is the first ...
... , ST. LOUIS ,  Aug. 2 K-V Pharmaceutical ... received notification from the New York Stock Exchange ("NYSE") on ... quantitative continued listing standards.  The NYSE informed the Company that ... criteria for the average closing price of a NYSE security ...
Cached Medicine Technology:OraVerse® Named as One of Dentistry Today's 'Top 100 Products' for Second Year 2OraVerse® Named as One of Dentistry Today's 'Top 100 Products' for Second Year 3K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 2K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 3K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 4K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 5K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 6K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 7K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 8K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 9
... The MicroAire® Hi Speed Pulse Lavage ... bone surfaces as well as cleansing ... Now a great system just got ... effective with the addition of ...
... Staple is a novel shape memory alloy bone ... of its Nitinol construction, the prongs of the ... upon application of a heating current. This results ... response of bone and cause adjustable compression across ...
... deformity of the ankle joint with ... fusion of the ankle joint, fractures ... where reconstruction is impossible, and fracture/dislocations ... severe arthritic changes and loss of ...
The Buechel-pappas™ Total Ankle Replacement is a time-tested system which is the result of more than twenty years of development, clinical investigation, and use. The components have been avai...
Medicine Products: